Erectile dysfunction · Review · 2026
Does combining shockwave with erection pills work better than one treatment?
In this review of 8 studies, men using shockwave with erection pills reached higher erection scores than with shockwave alone. Against pills alone there was no clear difference, and overall the gap was less certain. Gains were clearest in men with blood-flow problems and in one study of men with diabetes.
Possible extra help in some groups- studies
- 8
- men in the 8 studies
- 553
- kinds of single treatment compared: pills, shockwave, or either pills or prostaglandin
- 3
Good to know: 8 studies with different shockwave schedules and different single treatments as the comparison.
Quistini A, Fallara G, Tozzi M, et al. Andrology, 2026 · Read the paper ↗
How this study worked
What happened
- Compared with
- One treatment alone: erection pills, shockwave, or either pills or a prostaglandin drug
Erection scores: combination vs one treatment
Standardised difference (no units), with likely range · above zero favours the combination
Show the numbers
| Difference (standardised difference (no units)) | likely range | |
|---|---|---|
| All comparisons | +0.37 | −0.21 to 0.95 |
| vs shockwave alone | +0.61 | 0.13 to 1.09 |
| Blood-flow causes | +0.65 | 0.3 to 0.98 |
| Diabetes-related (one study) | +1.05 | 0.72 to 1.39 |
What the trials used
- Combination treatment
- All combination arms used Li-ESWT plus PDE5 inhibitor. Energy, session number, session spacing and total course varied across studies; detailed protocols are referenced in unavailable Table S1.
- Monotherapy comparators
- Control regimens included PDE5 inhibitors, Li-ESWT, or (in one study) either a PDE5 inhibitor or prostaglandin E1, depending on the study.
Who took part
Men with erection problems from blood-flow problems, diabetes, mixed causes or after prostate surgery, across 8 studies.
Side effects
The review does not report side effects.
All the numbers and the full appraisal
The results, in numbers.
Eight studies of erectile dysfunction were included. Table 1 arm counts sum to 284 participants in combination arms and 269 in monotherapy arms (553 total). However, the Results narrative reports 321 combination participants, while its monotherapy breakdown (186 PDE5i + 67 Li-ESWT + 16 PDE5i or PGE1) totals 269, implying 590 overall. The 37-person discrepancy in combination-arm counts is unresolved. Causes included vasculogenic, diabetes-related, mixed, and post-prostatectomy ED.
Baseline erectile function6 reported outcomes
Baseline erectile function
International Index of Erectile Function (IIEF; study questionnaires reported IIEF-5) standardized mean difference (SMD)
Combination vs monotherapy
No significant baseline difference was reported (SMD −0.04, 95% CI −0.21 to 0.13; p=0.6).
Analysis details and source
Meta-analysis authors transformed median (IQR) reports to mean (SD) using a Box–Cox method. Heterogeneity was high (I² 75–97% across outcomes); source-level raw means are not available in the main text. Nonsignificance does not show equivalence.
Follow-up erectile function
International Index of Erectile Function (IIEF; study questionnaires reported IIEF-5) standardized mean difference (SMD)
Combination vs monotherapy overall
The overall pooled contrast was not statistically significant (SMD 0.37, 95% CI −0.21 to 0.95; p=0.3).
Analysis details and source
Meta-analysis authors transformed median (IQR) reports to mean (SD) using a Box–Cox method. Heterogeneity was high (I² 75–97% across outcomes); source-level raw means are not available in the main text. Nonsignificance does not show equivalence.
Combination vs Li-ESWT monotherapy
International Index of Erectile Function (IIEF; study questionnaires reported IIEF-5) standardized mean difference (SMD)
Li-ESWT plus PDE5i vs Li-ESWT alone
In the subgroup whose monotherapy comparator was Li-ESWT, combination therapy favored IIEF scores (SMD 0.61, 95% CI 0.13 to 1.09; p=0.013). This is a subgroup pooled comparison, not an absolute score change.
Analysis details and source
Meta-analysis authors transformed median (IQR) reports to mean (SD) using a Box–Cox method. Heterogeneity was high (I² 75–97% across outcomes); source-level raw means are not available in the main text. Nonsignificance does not show equivalence.
Six-month IIEF sensitivity analysis
International Index of Erectile Function (IIEF; study questionnaires reported IIEF-5) standardized mean difference (SMD)
Combination vs monotherapy
The six-month subset favored combination therapy (SMD 0.58, 95% CI 0.05 to 1.12; p=0.033); studies and protocols remain heterogeneous.
Analysis details and source
Meta-analysis authors transformed median (IQR) reports to mean (SD) using a Box–Cox method. Heterogeneity was high (I² 75–97% across outcomes); source-level raw means are not available in the main text. Nonsignificance does not show equivalence.
Vasculogenic ED subgroup
International Index of Erectile Function (IIEF; study questionnaires reported IIEF-5) standardized mean difference (SMD)
Combination vs monotherapy in vasculogenic ED
The vasculogenic subgroup favored combination therapy (SMD 0.65, 95% CI 0.30 to 0.98; p<0.001).
Analysis details and source
Meta-analysis authors transformed median (IQR) reports to mean (SD) using a Box–Cox method. Heterogeneity was high (I² 75–97% across outcomes); source-level raw means are not available in the main text. Nonsignificance does not show equivalence.
Diabetes-related ED subgroup
International Index of Erectile Function (IIEF; study questionnaires reported IIEF-5) standardized mean difference (SMD)
Combination vs monotherapy in diabetes-related ED
The diabetes-related subgroup favored combination therapy (SMD 1.05, 95% CI 0.72 to 1.39; p<0.001). Only one included study enrolled men with diabetes-related ED (Verze et al. 2020, a retrospective matched-pair comparison of 78 vs 78 men; Section 3.1 and Table 1), so this subgroup result is not randomized evidence.
Analysis details and source
Meta-analysis authors transformed median (IQR) reports to mean (SD) using a Box–Cox method. Heterogeneity was high (I² 75–97% across outcomes); source-level raw means are not available in the main text. Nonsignificance does not show equivalence.
Erection Hardness Scale (EHS)1 reported outcome
Erection Hardness Scale (EHS)
Erection Hardness Scale (EHS) score; numeric estimate not stated in main text
No statistically significant difference between combination and monotherapy was reported for EHS in the overall or subgroup analyses (p>0.05). Exact estimates are in unavailable supplementary Figure S2.
Analysis details and source
The main text gives significance only; no estimate or interval is imputed.
IIEF at six months: combination vs Li-ESWT monotherapy5 reported outcomes
IIEF at six months: combination vs Li-ESWT monotherapy
International Index of Erectile Function (IIEF) standardized mean difference
Combination vs Li-ESWT monotherapy
In the six-month sensitivity analysis, the Li-ESWT monotherapy subgroup favored combination treatment (SMD 0.60, 95% CI 0.12 to 1.09; p=0.015).
Analysis details and source
Review-reported subgroup estimate; the supplementary plot contains study details not available in the main text. A nonsignificant result is not evidence of equivalence.
IIEF change within monotherapy
International Index of Erectile Function (IIEF) standardized mean difference
Monotherapy: post-treatment versus baseline (within-arm)
Across monotherapy studies, post-treatment IIEF did not differ significantly from baseline (SMD 0.94, 95% CI −1.53 to 3.41; p=0.5). This is a within-arm analysis, not a treatment comparison.
Analysis details and source
Review-reported pooled within-group estimate; study-level details are in the main-text Figure 3A forest plot, whose values are not given in the text. A nonsignificant result is not evidence of equivalence.
IIEF change within Li-ESWT monotherapy subgroup
International Index of Erectile Function (IIEF) standardized mean difference
Li-ESWT monotherapy subgroup: post-treatment versus baseline (within-arm)
Within the Li-ESWT monotherapy subgroup, post-treatment IIEF differed significantly from baseline (SMD 1.14, 95% CI 0.14 to 2.14; p=0.026). This does not establish a comparative treatment effect.
Analysis details and source
Review-reported pooled within-group estimate; study-level details are in the main-text Figure 3A forest plot, whose values are not given in the text. A nonsignificant result is not evidence of equivalence.
IIEF change within combination therapy
International Index of Erectile Function (IIEF) standardized mean difference
Combination therapy: post-treatment versus baseline (within-arm)
Across combination-therapy studies, post-treatment IIEF did not differ significantly from baseline (SMD 1.88, 95% CI −0.24 to 3.99; p=0.08). This is a within-arm analysis, not a treatment comparison.
Analysis details and source
Review-reported pooled within-group estimate; study-level details are in the main-text Figure 3B forest plot, whose values are not given in the text. A nonsignificant result is not evidence of equivalence.
IIEF change within combination therapy excluding Baccaglini
International Index of Erectile Function (IIEF) standardized mean difference
Combination therapy excluding Baccaglini et al.: post-treatment versus baseline (within-arm)
After excluding Baccaglini et al., the combination group showed a significant post-treatment versus baseline difference (SMD 2.39, 95% CI 0.26 to 4.52; p=0.04). This sensitivity result is within-arm and does not establish comparative efficacy.
Analysis details and source
Review-reported subgroup estimate; the supplementary plot contains study details not available in the main text. A nonsignificant result is not evidence of equivalence.
How treatment was delivered
All combination arms used Li-ESWT plus PDE5 inhibitor. Energy, session number, session spacing and total course varied across studies; detailed protocols are referenced in unavailable Table S1.
Control regimens included PDE5 inhibitors, Li-ESWT, or (in one study) either a PDE5 inhibitor or prostaglandin E1, depending on the study.
The main text does not report a pooled adverse-event outcome for the included comparison. No safety equivalence should be inferred.
All studies were rated high or serious risk of bias; the evidence was graded low overall.
Heterogeneity was high (I² 75–97% across outcomes), and participants, prior treatment, ED duration and protocols varied.
Seven studies were prospective and one retrospective. Sample sizes were small; randomization and blinding raised concerns.
No comparative combination studies of PRP or stem-cell therapy were found; cited supplement tables/figures were unavailable.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- All studies were rated high or serious risk of bias; the evidence was graded low overall.
- Heterogeneity was high (I² 75–97% across outcomes), and participants, prior treatment, ED duration and protocols varied.
- Seven studies were prospective and one retrospective. Sample sizes were small; randomization and blinding raised concerns.
- No comparative combination studies of PRP or stem-cell therapy were found; cited supplement tables/figures were unavailable.
Source-linked critical reading
Systematic review with meta-analysis
Technical source record
Complete main article XML read end-to-end, including methods, all Results, Discussion, conclusion and footnotes; the XML contains no funding or conflict-of-interest statement. Main-text effects, sample counts, comparators, transformation method, heterogeneity and risk-of-bias statements captured; supplement-only data not inferred.
The review suggests a possible added benefit from combining shockwave therapy with PDE5 inhibitors for some causes of ED, but the overall result was inconclusive and evidence quality was low.
Does adding a regenerative treatment to conventional therapy improve erectile function compared with either treatment alone? The available evidence addressed low-intensity Li-ESWT plus PDE5 inhibitor; no combination studies of PRP or stem-cell therapy met criteria.
Systematic review and meta-analysis of eight studies (553 men): seven prospective and one retrospective database analysis. The stated primary outcome was between-group IIEF at follow-up.
Eight studies. Table 1 sums to 284 combination and 269 monotherapy participants (553 total), whereas Results prose reports 321 combination participants and the same 269 monotherapy participants (implying 590 in total, although the same section reports 553 patients): an unresolved 37-person discrepancy.
All combination arms used Li-ESWT plus PDE5i. Energy, weekly applications, session duration and course length varied across trials; the detailed protocol table was not available.
Monotherapy was PDE5i, Li-ESWT, or, in one study, either PDE5i or prostaglandin E1, according to study. Therefore, the pooled contrast combines different control therapies.
Overall follow-up IIEF was not significantly different (SMD 0.37, 95% CI −0.21 to 0.95; p=0.3). A subgroup comparing Li-ESWT plus PDE5i with Li-ESWT alone favored combination (0.61, 0.13 to 1.09; p=0.013). EHS differences were not significant. The six-month Li-ESWT subgroup estimate was SMD 0.60 (95% CI 0.12–1.09; p=0.015). Within-arm analyses reported monotherapy SMD 0.94 (−1.53 to 3.41; p=0.5), Li-ESWT monotherapy subgroup 1.14 (0.14–2.14; p=0.026), combination 1.88 (−0.24 to 3.99; p=0.08), and combination excluding Baccaglini 2.39 (0.26–4.52; p=0.04). These pre/post estimates are not between-treatment effects. EHS had no significant pre/post finding (p>0.05); exact estimates were in an unavailable supplement.
The statistically significant IIEF findings were confined to the Li-ESWT comparator, six-month subset and vasculogenic/diabetes subgroups. Subgroup effects should not be generalized to the full ED population. The authors transformed medians/IQRs to means/SDs before synthesis.
The main text does not present pooled adverse-event results for this comparison.
Low-certainty evidence; high/serious risk of bias; high heterogeneity; varied ED causes, prior treatment and protocols; one retrospective study; no PRP or stem-cell combination evidence; supplements unavailable.
Findings apply to combination Li-ESWT/PDE5i and specific comparator subgroups. They do not identify a standardized shockwave regimen or guarantee an individual response.
Conduct larger, low-bias trials with explicit ED etiology/duration, prior PDE5i response, standardized Li-ESWT dose, prespecified validated outcomes and follow-up beyond six months.
Read the original article.
Comparative efficacy of combination therapy including regenerative therapies versus monotherapy for erectile dysfunction: A systematic review and meta-analysis.
Quistini A, Fallara G, Tozzi M, Depalma M, Damiano R, Palmieri A, Castiglione F, Salonia A, Bianchi R, Ferro M, Muneer A, Alnajjar HM, Pang KH. · Andrology · 2026
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →